Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
Total Valuation
BioCryst has a market cap or net worth of $2.10B. The enterprise value is $2.15B.
Market Cap$2.10B
Enterprise Value$2.15B
Share Statistics
BioCryst has 250,800,610 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding250,800,610
Owned by Insiders1.57%
Owned by Institutions3.88%
Financial Efficiency
BioCryst’s return on equity (ROE) is -2.21 and return on invested capital (ROIC) is 93.94%.
Return on Equity (ROE)-2.21
Return on Assets (ROA)0.51
Return on Invested Capital (ROIC)93.94%
Return on Capital Employed (ROCE)1.07
Revenue Per Employee1.51M
Profits Per Employee454.93K
Employee Count580
Asset Turnover1.70
Inventory Turnover3.53
Valuation Ratios
The current PE Ratio of BioCryst is 6.2. BioCryst’s PEG ratio is -0.02.
PE Ratio6.2
PS Ratio1.87
PB Ratio-13.74
Price to Fair Value-13.74
Price to FCF5.00
Price to Operating Cash Flow5.34
PEG Ratio-0.02
Income Statement
In the last 12 months, BioCryst had revenue of 874.84M and earned 263.86M in profits. Earnings per share was 1.26.
Revenue874.84M
Gross Profit855.76M
Operating Income340.99M
Pretax Income267.39M
Net Income263.86M
EBITDA347.65M
Earnings Per Share (EPS)1.26
Cash Flow
In the last 12 months, operating cash flow was 330.93M and capital expenditures -2.47M, giving a free cash flow of 328.46M billion.
Operating Cash Flow330.93M
Free Cash Flow328.46M
Free Cash Flow per Share1.31
Dividends & Yields
BioCryst pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.80
52-Week Price Change8.83%
50-Day Moving Average7.34
200-Day Moving Average7.98
Relative Strength Index (RSI)62.01
Average Volume (3m)4.38M
Important Dates
BioCryst upcoming earnings date is Apr 30, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
BioCryst as a current ratio of 2.06, with Debt / Equity ratio of -400.60%
Current Ratio2.06
Quick Ratio2.03
Debt to Market Cap0.29
Net Debt to EBITDA1.11
Interest Coverage Ratio4.32
Taxes
In the past 12 months, BioCryst has paid 3.53M in taxes.
Income Tax3.53M
Effective Tax Rate0.01
Enterprise Valuation
BioCryst EV to EBITDA ratio is 5.82, with an EV/FCF ratio of 6.18.
EV to Sales2.31
EV to EBITDA5.82
EV to Free Cash Flow6.18
EV to Operating Cash Flow6.14
Balance Sheet
BioCryst has $274.75M in cash and marketable securities with $477.33M in debt, giving a net cash position of -$202.58M billion.
Cash & Marketable Securities$274.75M
Total Debt$477.33M
Net Cash-$202.58M
Net Cash Per Share-$0.81
Tangible Book Value Per Share-$0.57
Margins
Gross margin is 97.74%, with operating margin of 38.98%, and net profit margin of 30.16%.
Gross Margin97.74%
Operating Margin38.98%
Pretax Margin30.56%
Net Profit Margin30.16%
EBITDA Margin39.74%
EBIT Margin39.58%
Analyst Forecast
The average price target for BioCryst is $21.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.63
Price Target Upside158.11% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast45.38%
EPS Growth Forecast92.85%